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ADRENAL SUPPRESSION FROM INTRADERMAL TRIAMCINOLONE*
A. DAVID McGUGAN, M.A., M.B.,** SAM SHUSTER, PrnD., M.B., B.S., M.R.C.P. AND
EVA BOTTOMS, B.Sc.
Because of the extensive use of intralesional
corticosteroids in the treatment of a wide variety
of dermatological conditions, (1, 2), it was decided
to investigate whether sufficient hormone was
absorbed after intradermal injection to induce
adrenal suppression; and if so, at what dose such
suppression might occur, and for how long.
Methods
Eighteen patients, male and female, aged 17 to
72 years, were studied. All were in-patients, not
confined to bed, with one of several dermatoses
including psoriasis and atopic dermatitis. None
had previously received corticosteroid therapy.
Blood was drawn between 9 and 11 a.m. to mini-
mize the effect of the diurnal variation in plasma
cortisol concentration. The samples were hepa-
rinized and the plasma was separated and stored
frozen until analyzed. After obtaining two control
blood samples, 0.63 to 2.5 ml. of triamcinolone
diacetate or triamcinolone acetonide tertiary
butyl acetate containing 40 mg. per ml. was in-
jected intradermally (in divided doses in volumes
of 0.3 ml. or less) into normal skin on the lateral
aspect of the thighs in 14 patients and intra-
lesionally into psoriatic plaques on the limb and
trunk in 4 patients. Further blood samples were
obtained on the following four or five days.
Plasma cortisol was measured as free (uncon-
jugated) 17 hydroxy-corticosteroid (17-OHCS) by
the method of Peterson et at. (3) with slight modi-
fications (4). Triamcinolone was used because the
16-OH group quenches the Porter-Silber reaction
(4); thus triamcinolone and its metabolites are not
measured by the present method. We could be
certain, therefore, that all plasma-free 17-OHCS
measured in this way was endogenous in origin.
Results
There was some fluctuation in the basal plasma
cortisol concentrations before triamcinolone was
injected, and several of the concentrations were
at or below the lower range of normal for this
method. This was technical in origin, due to high
blank readings from interfering chromogens.
Five patients received 100 mg. and three pa-
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tients 75 mg. of triamcinolone acetonide tertiary
butyl acetate intradermally or intralesionally(figures 1 and 2). Plasma cortisol concentrations
fell in all but one of these patients, in whom how-
ever blood was not obtained on the day after the
injection (figure 1). The degree to which the
plasma cortisol concentrations fell indicates vir-
tually complete suppression of adrenal secretion
of cortisol in six of the patients. By day six of the
experiment, that is five days after injection of
the triamcinolone, plasma cortisol concentrations
had returned to normal in all but one of the pa-
tients.
Six patients received 50 mg. of triamcinolone
acetonide tertiary butyl acetate nd the plasma
cortisol concentrations fell below normal in two
of these, but was normal again on the next day
(figure 3).
The four patients receiving 25 mg. of triamcino-
lone diacetate showed no significant depression of
their plasma cortisol concentrations (figure 4).
The results in the four patients receiving intra-
lesional triamcinolone derivatives were similar to
those receiving intradermal injections into normal
skin at the same concentration (figures 1—4).
Discussion
Our findings indicate that intradermal injec-
tions of triamcinolone derivatives can induce
adrenal suppression. With doses of 50mg. of triam-
cinolone acetonide tertiary butyl acetate, adrenal
suppression was found only occasionally and was
transient. By contrast, suppression was usual
when 75—100 mg. of triamcinolone acetonide terti-
ary butyl acetate was injected and this suppres-
sion persisted in most patients for up to four days.
This suggests that absorption of the steroid from
the skin was correspondingly prolonged. In this
respect the present results are similar to those
found when triamcinolone was injected into the
knee (5), when the possibility was considered that
the prolonged adrenal suppression was due to slow
absorption of corticosteroid bound by a component
of the joint capsule. Prolonged absorption could
also be due to insolubility of the steroid prepara-
tion (6).
The degree and duration of adrenal suppression
induced by 75—100 mg. of triamcinolone acetonide
tertiary butyl acetate is such that adrenal atrophy
could be induced by repeated injections. Further-
more with doses of this order, the usual contra-
indications to corticosteroid therapy apply. The
findings suggest that doses of triamcinolone diace-
tate of 25 mg. or less are unlikely to produce
systemic effects.
Summary
A single injection of 75—100 mg. triamcinolone
acetonide tertiary butyl acetate induced adrenal
suppression as measured by a decrease in plasma
cortisol concentration, which persisted up to four
or more days. By contrast, with 25 mg. of triam-
cinolone diacetate, or 50 mg. of triamcinolone
acetonide tertiary butyl acetate adrenal suppres-
sion was occasional and transient. It is concluded
that 25 mg. or less of triamcinolone diacetate
should be a safe dose for intralesional injection
therapy.
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